Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Large Growth in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a large growth in short interest in September. As of September 15th, there was short interest totalling 94,600 shares, a growth of 392.7% from the August 31st total of 19,200 shares. Currently, 8.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 448,700 shares, the days-to-cover ratio is currently 0.2 days.

Allarity Therapeutics Stock Performance

Shares of ALLR stock remained flat at $2.23 during mid-day trading on Friday. The stock had a trading volume of 88,952 shares, compared to its average volume of 210,758. Allarity Therapeutics has a one year low of $1.78 and a one year high of $666.00. The stock’s fifty day simple moving average is $0.77 and its 200-day simple moving average is $1.58.

Allarity Therapeutics (NASDAQ:ALLR) last released its earnings results on Monday, August 5th. The company reported ($0.11) earnings per share (EPS) for the quarter. Equities research analysts predict that Allarity Therapeutics will post -78.08 earnings per share for the current year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.